Marta Santisteban Eslava-rekin lankidetzan egindako argitalpenak (9)

2024

  1. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

2023

  1. Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies

    Biomedicines, Vol. 11, Núm. 2

2019

  1. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach

    British Journal of Clinical Pharmacology, Vol. 85, Núm. 8, pp. 1670-1683

2018

  1. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

    Breast Journal, Vol. 24, Núm. 4, pp. 473-479

2015

  1. 37th Annual San Antonio Breast Cancer Symposium. Summary of the most important translational and clinical contributions

    Revista de Senologia y Patologia Mamaria

  2. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

2013

  1. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: A retrospective cohort study

    Journal of Neuro-Oncology

2010

  1. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

    Cancer Chemotherapy and Pharmacology, Vol. 65, Núm. 3, pp. 457-465

2008

  1. Hormonal therapy in breast cancer

    Revista de medicina de la Universidad de Navarra, Vol. 52, Núm. 1, pp. 40-48